BioLineRx (BLRX) Accounts Payables (2010 - 2025)

BioLineRx's Accounts Payables history runs 16 years deep, the most recent figure standing at $3.5 million for Q4 2025.

• On a quarterly basis, Accounts Payables fell 37.44% year-over-year to $3.5 million in Q4 2025; TTM through Dec 2025 was $3.5 million, a 37.44% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 37.44% from the prior year.
• Accounts Payables eased to $3.5 million in Q4 2025 per BLRX's latest filing, from $3.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $10.9 million in Q4 2023 and bottomed at $3.5 million in Q2 2025.
• The 5-year median for Accounts Payables is $5.8 million (2021), against an average of $6.1 million.
• Across the five-year window, Accounts Payables surged 56.03% in 2023 and slumped 48.63% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $5.6 million in 2021, then increased by 25.13% to $7.0 million in 2022, then jumped by 56.03% to $10.9 million in 2023, then plunged by 48.63% to $5.6 million in 2024, then tumbled by 37.44% to $3.5 million in 2025.
• Per Business Quant, the three latest BLRX Accounts Payables figures stand at $3.5 million (Q4 2025), $3.5 million (Q3 2025), and $3.5 million (Q2 2025).